AEOL 10150

Drug Profile

AEOL 10150

Alternative Names: AEOL-10150; MnTDEIP

Latest Information Update: 29 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Duke University; National Jewish Medical and Research Center
  • Developer Aeolus Pharmaceuticals Inc; National Institutes of Health (USA); National Jewish Medical and Research Center; United States Army Medical Research Institute of Chemical Defense; University of Colorado at Denver
  • Class Oxidoreductases; Porphyrins; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Antioxidants; Free radical scavengers; Oxygen radical scavengers; Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Acute radiation syndrome; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute radiation syndrome
  • Preclinical Acute lung injury; Gastrointestinal disorders; Idiopathic pulmonary fibrosis; Lung disorders; Poisoning; Radiation injuries; Skin disorders; Solid tumours
  • Suspended Amyotrophic lateral sclerosis
  • Discontinued Chronic obstructive pulmonary disease; Cystic fibrosis; Diabetes mellitus; Mucositis; Spinal cord injuries; Stroke

Most Recent Events

  • 08 Jun 2017 AEOL 10150 receives Fast Track designation for Acute radiation syndrome [SC] (In volunteers) in USA
  • 23 Mar 2017 Biomedical Advanced Research and Development Authority elects not to exercise additional options for pulmonary injury associated with Acute radiation syndrome and delayed effects of radiation exposure
  • 23 Mar 2017 Pharmacodynamics data from preclinical trials in Pulmonary acute radiation syndrome released by Aeolus Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top